These large studies will also scrutinise the sequential use of biomarkers and explore the potential added value of genotyping individuals for common genetic risk variants of MASLD, such as PNPLA3 I148M, as was recently suggested for individuals with type 2 diabetes and an indeterminate FIB-4 result [72]. The gene discussed is PNPLA3; the disease is type 2 diabetes mellitus.